EUR USD GBP
+353-1-416-8900REST OF WORLD
1-800-526-8630U.S. (TOLL FREE)

Neurofibromatoses Type I (Von Recklinghausen's Disease) - Pipeline Review, H2 2016

  • ID: 4030267
  • Report
  • December 2016
  • 42 pages
  • Global Markets Direct
1 of 4
Neurofibromatoses Type I (Von Recklinghausen’s Disease) - Pipeline Review, H2 2016

Summary:

The latest Pharmaceutical and Healthcare disease pipeline guide Neurofibromatoses Type I - Pipeline Review, H2 2016, provides an overview of the Neurofibromatoses Type I (Genetic Disorders) pipeline landscape.

Neurofibromatosis type 1 (NF1), also called von Recklinghausen's disease, is a rare genetic disorder characterized by the development of multiple noncancerous (benign) tumors of nerves and skin (neurofibromas). This is transmitted on chromosome 17 and is caused by mutation of the NF1 gene. Symptoms include liver enlargement, glioma, Lisch nodules and pheochromocytoma. Treatment includes pain medications, surgery, chemotherapy and radiation therapy.

Report Highlights:

The latest Pharmaceutical and Healthcare latest pipeline guide Neurofibromatoses Type I - Pipeline Review, H2 2016, provides comprehensive information on the therapeutics under development for Neurofibromatoses Type I (Genetic Disorders), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Neurofibromatoses Type I (Genetic Disorders) pipeline guide also reviews of key players involved in therapeutic development for Neurofibromatoses Type I (Von Recklinghausen’s Disease) and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Phase II, Preclinical and Discovery stages are 1, 2 and 1 respectively. Similarly, the Universities portfolio in Discovery stages comprises 1 molecules, respectively.

Neurofibromatoses Type I (Genetic Disorders) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from our proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources.

Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope:

- The pipeline guide provides a snapshot of the global therapeutic landscape of Neurofibromatoses Type I (Genetic Disorders).
- The pipeline guide reviews pipeline therapeutics for Neurofibromatoses Type I (Genetic Disorders) by companies and universities/research institutes based on information derived from company and industry-specific sources.
- The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
- The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
- The pipeline guide reviews key companies involved in Neurofibromatoses Type I (Genetic Disorders) therapeutics and enlists all their major and minor projects.
- The pipeline guide evaluates Neurofibromatoses Type I (Genetic Disorders) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
- The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
- The pipeline guide reviews latest news related to pipeline therapeutics for Neurofibromatoses Type I (Genetic Disorders)

Reasons to Buy:

- Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
- Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
- Find and recognize significant and varied types of therapeutics under development for Neurofibromatoses Type I (Genetic Disorders).
- Classify potential new clients or partners in the target demographic.
- Develop tactical initiatives by understanding the focus areas of leading companies.
- Plan mergers and acquisitions meritoriously by identifying key players and it’s most promising pipeline therapeutics.
- Formulate corrective measures for pipeline projects by understanding Neurofibromatoses Type I (Genetic Disorders) pipeline depth and focus of Indication therapeutics.
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
- Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.
READ MORE
Note: Product cover images may vary from those shown
2 of 4
Introduction

Neurofibromatoses Type I (Von Recklinghausen’s Disease) Overview

Therapeutics Development

Pipeline Products for Neurofibromatoses Type I (Von Recklinghausen’s Disease) - Overview

Pipeline Products for Neurofibromatoses Type I (Von Recklinghausen’s Disease) - Comparative Analysis

Neurofibromatoses Type I (Von Recklinghausen’s Disease) - Therapeutics under Development by Companies

Neurofibromatoses Type I (Von Recklinghausen’s Disease) - Therapeutics under Investigation by Universities/Institutes

Neurofibromatoses Type I (Von Recklinghausen’s Disease) - Pipeline Products Glance

Clinical Stage Products

Early Stage Products

Neurofibromatoses Type I (Von Recklinghausen’s Disease) - Products under Development by Companies

Neurofibromatoses Type I (Von Recklinghausen’s Disease) - Products under Investigation by Universities/Institutes

Neurofibromatoses Type I (Von Recklinghausen’s Disease) - Companies Involved in Therapeutics Development

Alexion Pharmaceuticals Inc

AstraZeneca Plc

Celldex Therapeutics Inc

Neurofibromatoses Type I (Von Recklinghausen’s Disease) - Therapeutics Assessment

Assessment by Monotherapy Products

Assessment by Target

Assessment by Mechanism of Action

Assessment by Route of Administration

Assessment by Molecule Type

Drug Profiles

asfotase alfa - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

CDX-0158 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

selumetinib sulfate - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Small Molecules for Neurofibromatoses Type I - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

VAL-0524 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Neurofibromatoses Type I (Von Recklinghausen’s Disease) - Dormant Projects

Appendix

Methodology

Coverage

Secondary Research

Primary Research

Expert Panel Validation

Contact Us

Disclaimer

List of Tables:

Number of Products under Development for Neurofibromatoses Type I (Von Recklinghausen’s Disease), H2 2016

Number of Products under Development for Neurofibromatoses Type I (Von Recklinghausen’s Disease) - Comparative Analysis, H2 2016

Number of Products under Development by Companies, H2 2016

Number of Products under Investigation by Universities/Institutes, H2 2016

Comparative Analysis by Clinical Stage Development, H2 2016

Comparative Analysis by Early Stage Development, H2 2016

Products under Development by Companies, H2 2016

Products under Investigation by Universities/Institutes, H2 2016

Neurofibromatoses Type I (Von Recklinghausen’s Disease) - Pipeline by Alexion Pharmaceuticals Inc, H2 2016

Neurofibromatoses Type I (Von Recklinghausen’s Disease) - Pipeline by AstraZeneca Plc, H2 2016

Neurofibromatoses Type I (Von Recklinghausen’s Disease) - Pipeline by Celldex Therapeutics Inc, H2 2016

Assessment by Monotherapy Products, H2 2016

Number of Products by Stage and Target, H2 2016

Number of Products by Stage and Mechanism of Action, H2 2016

Number of Products by Stage and Route of Administration, H2 2016

Number of Products by Stage and Molecule Type, H2 2016

Neurofibromatoses Type I (Von Recklinghausen’s Disease) - Dormant Projects, H2 2016

List of Figures:

Number of Products under Development for Neurofibromatoses Type I (Von Recklinghausen’s Disease), H2 2016

Number of Products under Development for Neurofibromatoses Type I (Von Recklinghausen’s Disease) - Comparative Analysis, H2 2016

Number of Products under Development by Companies, H2 2016

Comparative Analysis by Early Stage Products, H2 2016

Assessment by Monotherapy Products, H2 2016

Number of Products by Targets, H2 2016

Number of Products by Stage and Targets, H2 2016

Number of Products by Mechanism of Actions, H2 2016

Number of Products by Stage and Mechanism of Actions, H2 2016

Number of Products by Routes of Administration, H2 2016

Number of Products by Stage and Routes of Administration, H2 2016

Number of Products by Molecule Types, H2 2016

Number of Products by Stage and Molecule Types, H2
Note: Product cover images may vary from those shown
3 of 4
  • Alexion Pharmaceuticals Inc
  • AstraZeneca Plc
  • Celldex Therapeutics Inc
Note: Product cover images may vary from those shown
4 of 4
Note: Product cover images may vary from those shown
Adroll
adroll